FLXN insider filings

Flexion Therapeutics Inc — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-11-23. Screen FLXN transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for FLXN between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Flexion Therapeutics Inc

FiledFormInsiderReported transactionsSource
2021-11-234Newtyn Management, LLC — 10% ownerCode (U): 5,900,000EDGAR
2021-11-194Stejbach Mark — DirectorDisposition to issuer (D): 12,631 @ $8.50 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 7,000 (derivative) · +1 moreEDGAR
2021-11-194Lukatch Heath — DirectorDisposition to issuer (D): 9,000 @ $8.50 · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 7,000 (derivative) · Disposition to issuer (D): 7,000 (derivative)EDGAR
2021-11-194Kwo Elizabeth — DirectorDisposition to issuer (D): 4,500 @ $8.50 · Disposition to issuer (D): 32,000 (derivative) · Disposition to issuer (D): 7,000 (derivative)EDGAR
2021-11-194Koppikar Utpal — DirectorDisposition to issuer (D): 32,000 (derivative)EDGAR
2021-11-194Levine Mark S. — General CounselDisposition to issuer (D): 133,486 @ $8.50 · Disposition to issuer (D): 125,000 (derivative) · Disposition to issuer (D): 33,333 (derivative) · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 15,500 (derivative) · Disposition to issuer (D): 20,000 (derivative)EDGAR
2021-11-194Muzikant Adam — Chief Business OfficerDisposition to issuer (D): 103,666 @ $8.50 · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 16,667 (derivative) · Disposition to issuer (D): 11,000 (derivative) · Disposition to issuer (D): 20,000 (derivative)EDGAR
2021-11-194Layman Melissa — Chief Commercial OfficerDisposition to issuer (D): 103,956 @ $8.50 · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 20,100 (derivative)EDGAR
2021-11-194Willwerth Christina — Chief Strategy OfficerDisposition to issuer (D): 141,241 @ $8.50 · Disposition to issuer (D): 25,830 (derivative) · Disposition to issuer (D): 32,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 5,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · +5 moreEDGAR
2021-11-194Andrews William T. — Chief Medical OfficerDisposition to issuer (D): 34,250 @ $8.50 · Disposition to issuer (D): 205,500 (derivative)EDGAR
2021-11-194Clayman Michael D. — President and CEO, DirectorDisposition to issuer (D): 335,498 @ $8.50 · Disposition to issuer (D): 373,769 @ $8.50 · Disposition to issuer (D): 24,600 @ $8.50 · Disposition to issuer (D): 388,683 @ $8.50 · Disposition to issuer (D): 136,530 (derivative) · Disposition to issuer (D): 200,000 (derivative) · +7 moreEDGAR
2021-11-194Wentworth Kerry — Chief Regulatory OfficerDisposition to issuer (D): 140,843 @ $8.50 · Disposition to issuer (D): 6,000 @ $8.50 · Disposition to issuer (D): 24,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · +5 moreEDGAR
2021-11-194Canute Scott A — DirectorDisposition to issuer (D): 9,000 @ $8.50 · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · +3 moreEDGAR
2021-11-194MAHAFFY PATRICK J — DirectorDisposition to issuer (D): 39,824 @ $8.50 · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · +3 moreEDGAR
2021-11-194MERRIFIELD C ANN — DirectorDisposition to issuer (D): 19,000 @ $8.50 · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · +3 moreEDGAR
2021-11-194MILINAZZO ALAN — DirectorDisposition to issuer (D): 27,450 @ $8.50 · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 9,000 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 12,500 (derivative) · +3 moreEDGAR
2021-11-194COLELLA SAMUEL D — DirectorDisposition to issuer (D): 9,000 @ $8.50 · Disposition to issuer (D): 1,000 @ $8.50 · Disposition to issuer (D): 72,035 @ $8.50 · Disposition to issuer (D): 5,000 @ $8.50 · Disposition to issuer (D): 994,129 @ $8.50 · Disposition to issuer (D): 5,871 @ $8.50 · +12 moreEDGAR
2021-11-194DRISCOLL FREDERICK W — Chief Financial OfficerDisposition to issuer (D): 30,680 @ $8.50 · Disposition to issuer (D): 168,000 (derivative)EDGAR
2021-08-044Andrews William T. — Chief Medical OfficerGrant/award (A): 34,250 @ $0 · Grant/award (A): 205,500 (derivative) @ $0EDGAR
2021-07-204Willwerth Christina — Chief Strategy OfficerSale (S): 3,945 @ $6.45EDGAR
2021-07-204Muzikant Adam — Chief Business OfficerSale (S): 1,870 @ $6.45EDGAR
2021-07-204Levine Mark S. — General CounselSale (S): 3,945 @ $6.45EDGAR
2021-07-204Clayman Michael D. — President and CEO, DirectorTax withholding (F): 13,859EDGAR
2021-07-204Wentworth Kerry — Chief Regulatory OfficerSale (S): 3,944 @ $6.45EDGAR
2021-07-124Koppikar Utpal — DirectorGrant/award (A): 32,000 (derivative) @ $0EDGAR
2021-06-284Kwo Elizabeth — DirectorGrant/award (A): 4,500 @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2021-06-284Stejbach Mark — DirectorGrant/award (A): 4,500 @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2021-06-284Lukatch Heath — DirectorGrant/award (A): 4,500 @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2021-06-284Muzikant Adam — Chief Business OfficerGrant/award (A): 2,081 @ $7.78EDGAR
2021-06-284Clayman Michael D. — President and CEO, DirectorGrant/award (A): 1,700 @ $7.78EDGAR
2021-06-284Wentworth Kerry — Chief Regulatory OfficerGrant/award (A): 539 @ $7.78EDGAR
2021-06-284Canute Scott A — DirectorGrant/award (A): 4,500 @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2021-06-284MAHAFFY PATRICK J — DirectorGrant/award (A): 4,500 @ $0 · Grant/award (A): 12,500 (derivative) @ $0EDGAR
2021-06-284MERRIFIELD C ANN — DirectorGrant/award (A): 4,500 @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2021-06-284MILINAZZO ALAN — DirectorGrant/award (A): 4,500 @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2021-06-284COLELLA SAMUEL D — DirectorGrant/award (A): 4,500 @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2021-06-034DRISCOLL FREDERICK W — Chief Financial OfficerGrant/award (A): 28,000 @ $0 · Grant/award (A): 168,000 (derivative) @ $0EDGAR
2021-05-124Arkowitz David — Chief Financial OfficerSale (S): 2,229 @ $7.23EDGAR
2021-03-234Clayman Michael D. — President and CEO, DirectorGift (G): 4,762 @ $0 · Gift (G): 21,099 @ $0EDGAR
2021-03-164Layman Melissa — Chief Commercial OfficerSale (S): 4,520 @ $11.80EDGAR
2021-03-124/ACOLELLA SAMUEL D — DirectorOther (J): 2,198 @ $0EDGAR
2021-03-034Muzikant Adam — Chief Business OfficerGrant/award (A): 30,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0EDGAR
2021-03-034Willwerth Christina — Chief Strategy OfficerGrant/award (A): 30,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0EDGAR
2021-03-034Levine Mark S. — General CounselGrant/award (A): 30,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0EDGAR
2021-03-034Layman Melissa — Chief Commercial OfficerGrant/award (A): 20,100 @ $0 · Grant/award (A): 30,150 (derivative) @ $0EDGAR
2021-03-034Clayman Michael D. — President and CEO, DirectorGrant/award (A): 106,100 @ $0 · Grant/award (A): 159,150 (derivative) @ $0EDGAR
2021-03-034Wentworth Kerry — Chief Regulatory OfficerGrant/award (A): 30,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0EDGAR
2021-03-034Arkowitz David — Chief Financial OfficerGrant/award (A): 30,000 @ $0 · Grant/award (A): 41,900 @ $0 · Grant/award (A): 20,000 (derivative) @ $0EDGAR
2021-03-034KELLEY SCOTT — Chief Medical OfficerGrant/award (A): 30,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0EDGAR
2021-01-294Clayman Michael D. — President and CEO, DirectorGrant/award (A): 119,500 @ $0 · Tax withholding (F): 8,776 @ $12.37EDGAR

Recent 8-K events — Flexion Therapeutics Inc

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2021-11-198-K1.01 — Entry into a Material Definitive Agreement
1.02 — Termination of a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2021-10-128-K1.01 — Entry into a Material Definitive Agreement
2.02 — Results of Operations and Financial Condition
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2021-08-048-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2021-07-128-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2021-06-258-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2021-05-128-K2.02 — Results of Operations and Financial Condition
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2021-05-118-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2021-04-138-K2.02 — Results of Operations and Financial Condition
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2021-04-058-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2021-03-108-K2.02 — Results of Operations and Financial Condition
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=FLXN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs